Pharma

The Diabetes Prevention Program (Knowler et al., 2002, NEJM) randomised 3,234 high-risk adults to intensive lifestyle intervention, metformin or placebo. After 2.8 years, lifestyle intervention reduced diabetes incidence by 58 per cent versus placebo. Metformin reduced it by 31 per cent. Lifestyle was nearly twice as effective as the drug across every demographic subgroup.

This is because the lifestyle arm addressed root causes: participants lost 7 per cent of body weight through dietary change and 150 minutes per week of moderate exercise. These changes restored insulin sensitivity at the cellular level by reducing visceral fat, improving mitochondrial function and normalising hepatic glucose output. Metformin merely suppressed hepatic glucose production without addressing the underlying metabolic dysfunction.

The 15-year follow-up (DPP Research Group, Lancet, 2015) confirmed that lifestyle intervention delayed diabetes onset by four years on average versus metformin's two years. Despite this, metformin prescriptions for pre-diabetes have increased by over 400 per cent since the trial published. The cheaper, more effective intervention generates no pharmaceutical revenue.

The Women's Health Initiative (Rossouw et al., 2002, JAMA) randomised 16,608 postmenopausal women to combined oestrogen-progestin HRT or placebo. The trial was stopped early at 5.2 years because the treatment group showed a 26 per cent increased risk of invasive breast cancer (HR 1.26, 95% CI: 1.00 to 1.59), a 29 per cent increase in coronary heart disease and a 41 per cent increase in stroke.

This is because exogenous oestrogen and synthetic progestins stimulate oestrogen receptor-positive breast cell proliferation and inhibit apoptosis. The WHI demonstrated that the risks became apparent after approximately three to four years of use and accumulated with duration. Prior to the WHI, HRT had been prescribed to approximately 15 million American women based on observational data suggesting cardiovascular protection.

Following publication, HRT prescriptions dropped by 50 per cent in the United States and breast cancer incidence fell by 6.7 per cent within a single year (Ravdin et al., 2007, NEJM). This natural experiment demonstrated that the drug was causing a measurable fraction of the national breast cancer burden. Risk communication remains poor: many women are still not informed of the WHI findings before starting treatment.

Bauer et al. (2021, Nature Reviews Endocrinology) conducted a consensus statement signed by 91 scientists reviewing the evidence on prenatal paracetamol (acetaminophen) exposure. Meta-analyses of over 200,000 mother-child pairs found a 20 to 30 per cent increased risk of ADHD and a 20 per cent increased risk of autism spectrum disorder with prenatal use, with the association strengthening with duration and dose of exposure.

This is because paracetamol crosses the placenta freely and disrupts foetal endocrine signalling. It inhibits prostaglandin synthesis in the developing brain, interferes with testosterone production in male foetuses (reducing anogenital distance, a marker of androgen exposure) and depletes glutathione, the primary antioxidant protecting the foetal brain from oxidative stress. These mechanisms operate during critical developmental windows.

Despite this evidence, paracetamol remains the only analgesic recommended during pregnancy. Over 65 per cent of pregnant women in Western countries use it at least once. No regulatory agency has issued a warning, and package inserts in most countries still state it is "generally considered safe" in pregnancy. The disconnect between the evidence and the guidance is striking.

The Lancet published a Global Research on Antimicrobial Resistance (GRAM) study in 2022 estimating that bacterial antimicrobial resistance (AMR) was directly responsible for 1.27 million deaths worldwide in 2019, with a further 4.95 million deaths associated with resistant infections. This makes AMR a larger killer than HIV/AIDS (864,000 deaths) or malaria (643,000 deaths) in the same year.

This is because antibiotics exert selective pressure on bacterial populations. Subtherapeutic doses, incomplete courses and prophylactic use in livestock select for resistant strains. Approximately 73% of all antibiotics sold globally are used in animal agriculture, primarily for growth promotion and disease prevention in concentrated feeding operations (Van Boeckel et al. 2019, Science). Resistant genes transfer between bacterial species via horizontal gene transfer, plasmids and transposons.

Alexander Fleming warned in his 1945 Nobel Prize lecture that misuse of penicillin would breed resistant organisms. Eighty years later, the WHO lists AMR as one of the top 10 global public health threats. New antibiotic development has collapsed: only 2 novel antibiotic classes have been approved since 2000, compared with 16 between 1940 and 1970. The pharmaceutical industry abandoned antibiotic R&D because the return on investment is low: effective antibiotics cure infections in days, while chronic disease drugs generate lifetime revenue.

Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, moxifloxacin) are among the most prescribed antibiotics globally, with over 26 million prescriptions annually in the United States alone. A meta-analysis by Stephenson et al. (2013, Sports Medicine) pooling 8 studies found fluoroquinolone use increased the risk of Achilles tendon rupture by 4.3-fold (95% CI: 3.2 to 5.7). The mechanism is direct: fluoroquinolones chelate magnesium ions essential for type I collagen cross-linking in tendon fibroblasts, causing matrix metalloproteinase upregulation and collagen degradation.

This is because fluoroquinolones are mitochondrial toxins. Kalghatgi et al. (2013, Science Translational Medicine) demonstrated that clinically relevant doses of ciprofloxacin caused oxidative damage to mitochondrial DNA in mammalian cells, not just bacterial DNA. The FDA issued its strongest black box warning for fluoroquinolones in 2016, noting risks of tendon rupture, peripheral neuropathy and central nervous system effects. Despite this, they remain first-line therapy for uncomplicated urinary tract infections in many NHS trusts.

The practical consequence is that a class of antibiotics prescribed for minor infections carries the risk of permanent connective tissue damage. Patients over sixty, those taking corticosteroids and athletes are at highest risk. The damage can appear weeks after the final dose and may be irreversible. This leads to a situation where a three-day course of antibiotics for a urinary tract infection can end an athletic career.

Proton pump inhibitors (omeprazole, lansoprazole, esomeprazole) are among the most prescribed drugs in the world, with 15.5 million NHS prescriptions in England per year. Reimer et al. (2009, Gastroenterology) conducted a randomised controlled trial showing that healthy volunteers given 8 weeks of PPI therapy developed rebound acid hypersecretion upon discontinuation, with 44% experiencing clinically significant dyspepsia that persisted for at least 4 weeks. None had symptoms before the trial began.

This is because PPIs suppress the hydrogen-potassium ATPase pump in gastric parietal cells, reducing acid output by up to 99%. The body compensates by upregulating gastrin production, stimulating parietal cell proliferation. When the PPI is withdrawn, the expanded parietal cell mass produces more acid than baseline. The patient feels worse than before they started, reinforcing the belief that they need the medication.

Haenisch et al. (2015, European Journal of Neurology) found a 44% increased risk of dementia in elderly PPI users (HR 1.44, 95% CI: 1.36 to 1.52), potentially through impaired vitamin B12 absorption. The drug creates a dependency cycle: treat reflux, cause rebound, continue prescribing. A Cochrane review found that 25 to 70% of PPI prescriptions in hospital settings lack an appropriate clinical indication.

In 1960, a UK child received approximately seven routine vaccine doses covering diphtheria, tetanus, pertussis, polio and smallpox. By 2024, the NHS schedule administers 18 doses by age 5, covering 12 distinct diseases through combination and standalone vaccines.

The steepest expansion occurred after 2000, with MenC (1999), PCV (2006), rotavirus (2013), MenB (2015) and hepatitis B (2017) entering in rapid succession. Each addition was recommended by the JCVI. No long-term controlled trial has examined the cumulative effects of the complete schedule as administered.

The rubella component of Priorix is grown in MRC-5 cells, a human diploid cell line derived from the lung tissue of a 14-week male foetus aborted in 1966. MMRVaxPro uses WI-38 cells for the same purpose, a separate foetal cell line from 1962. The polio component of Infanrix hexa and the rotavirus vaccine Rotarix are both produced in Vero cells, derived from African green monkey kidney tissue.

Formaldehyde appears as a trace manufacturing residual in Infanrix hexa, used to inactivate toxin components. Prevenar 13 contains 0.1 mg of polysorbate 80 per dose, the same emulsifier class shown by Chassaing (2015) to erode the gut mucus barrier in mouse models. Every ingredient is listed in the manufacturer SPC, publicly available on the electronic medicines compendium.

Moncrieff et al. (2022) published an umbrella review in Molecular Psychiatry (the most cited paper in the journal's history) systematically examining the serotonin hypothesis of depression. The review analysed 17 major systematic reviews and meta-analyses covering serotonin levels, serotonin metabolites, serotonin receptors, serotonin transporter levels, tryptophan depletion studies and SERT gene-stressor interactions. The conclusion: "there is no consistent evidence of there being an association between serotonin and depression."

This is because the serotonin hypothesis originated in the 1960s as a speculative model, not an established fact. Pharmaceutical companies adopted and marketed the "chemical imbalance" narrative because it simplified the sales pitch: your brain lacks serotonin, our drug restores it. Lacasse and Leo (2005, PLoS Medicine) documented that direct-to-consumer advertisements for SSRIs routinely claimed that depression was caused by a "chemical imbalance in the brain" despite no peer-reviewed evidence supporting this claim.

SSRI antidepressants generate approximately $15 billion in annual global revenue. Kirsch et al. (2008, PLoS Medicine) analysed all FDA-submitted clinical trial data for the 6 most prescribed antidepressants and found that the drug-placebo difference was clinically insignificant for mild and moderate depression, meeting the clinical significance threshold only for the most severely depressed patients. The drugs work. They just do not work because they fix a serotonin deficit, because no such deficit has ever been reliably demonstrated.

Human colostrum contains secretory IgA at concentrations of up to 5 mg/ml, alongside lactoferrin, lysozyme and over 200 human milk oligosaccharides. These are the same immunoglobulins that pasteurisation destroys in bovine milk, with 59% of IgA lost during standard heat treatment. The infant receives targeted, pathogen-specific antibodies shaped by the mother's immune history.

A prospective cohort of 4,164 infants found exclusive breastfeeding for four months significantly reduced respiratory and gastrointestinal infections. Protection against lower respiratory tract infections persisted to age four in children breastfed for six months or longer, with an adjusted odds ratio of 0.71.

A 26-year longitudinal study of 45 subjects measured antibody half-lives following natural infection. Measles antibodies showed a half-life of 3,014 years, effectively lifelong. By contrast, MMR vaccine efficacy declines from 97% initially to approximately ninety one percent by age 26 to 31, with 15% of two-dose vaccinees lacking protective IgG in long-term follow-up.

The pattern holds across diseases. Natural pertussis immunity lasts an estimated 30 or more years, while acellular pertussis vaccine protection drops to 41% after 8 years. Varicella reinfection rates increase 12-fold within 8 years of single-dose vaccination and in each case natural immunity substantially outlasts vaccine-induced protection.

Statins inhibit HMG-CoA reductase, the enzyme that produces both cholesterol and coenzyme Q10 (CoQ10). Littarru and Langsjoen (2007, Biofactors) meta-analysed 18 studies and found that statin therapy reduces plasma CoQ10 by 16 to 54 per cent (mean approximately 40 per cent). CoQ10 is essential for mitochondrial electron transport chain function, producing 95 per cent of cellular ATP. The organ with the highest CoQ10 demand is the heart.

This is because both cholesterol and CoQ10 share the mevalonate pathway. By blocking HMG-CoA reductase, statins cannot selectively reduce cholesterol without simultaneously reducing CoQ10 synthesis. The result is a drug prescribed to protect the heart that depletes the primary energy substrate the heart requires. Statin-induced myopathy (affecting 10 to 29 per cent of users) is likely mediated by CoQ10 depletion in skeletal muscle mitochondria.

Despite this well-documented mechanism, no statin prescription in the UK or US includes mandatory CoQ10 supplementation guidance. In contrast, Canada added CoQ10 supplementation to the statin monograph in 2019. A meta-analysis of 12 RCTs (Qu et al., 2018, BMC Cardiovascular Disorders) found that CoQ10 supplementation reduced statin-associated muscle symptoms by 37 per cent. The pharmaceutical industry has no incentive to promote co-supplementation that might reduce treatment adherence.